Funded Project Details - FY2021
|Title:|| Dopamine treatments for diabetic retinopathy|
Machelle T. Pardue
|Congressional District Code:
|| January 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Diabetic retinopathy (DR) is already the leading cause of blindness in working age adults, and the incidence of DR is predicted to double in the US by 2050 (NIH National Eye Institute data). With the prevalence of diabetes in veterans significantly higher than the civilian population, it is imperative that we develop new and more effective treatments for vision loss caused by DR. In the last funding cycle, we identified a novel neuroprotective agent for early stage DR: dopamine. Our research con...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.